Table 1 Characteristics of the cohort
|  | All (N = 340) | Asthma N = 200 | No asthma N = 141 | p value |
|---|---|---|---|---|
Age, mean (SD) | 13.4 (4.8) | 12.5 (4.6) | 14.7 (5.0) | 4.90E − 05 |
Sex female, no. (%) | 164 (48%) | 83 (42%) | 81 (57%) | 0.0042 |
Race/ethnicity, no. (%) |  |  |  | 3.93E − 06 |
 Asian | 23 (6.7%) | 4 (2.0%) | 19 (13.5%) |  |
 Black | 61 (17.9%) | 43 (21.5%) | 18 (12.8%) |  |
 Latino | 86 (25.2%) | 63 (31.5%) | 23 (16.3%) |  |
 Multiple races or unknown | 30 (8.8%) | 15 (7.5%) | 15 (10.6%) |  |
 White | 141 (41.3%) | 75 (37.5%) | 66 (46.8%) |  |
aAsthma medications prescribed, no. (%) | ||||
 β-Agonist | 190 (56.0%) | 190 (95.0%) | 0 (0%) |  |
 ICS | 44 (13.0%) | 44 (22.0%) | 0 (0%) |  |
 ICS/long-acting β-antagonist | 55 (16.1%) | 55 (27.5%) | 0 (0%) |  |
 Leukotriene receptor antagonist | 47 (13.8%) | 47 (23.5%) | 0 (0%) |  |
 Omalizumab | 5 (1.5%) | 5 (2.5%) | 0 (0%) |  |
ACT score, mean (SD) | 20.1 (5.3) | 16.6 (4.2) | 25 (0.0) |  < 2e − 16 |
FEV1% predicted, mean (SD) | 88 (15.4) | 86 (17.0) | 90 (13.1) | 0.022 |
FEV1/FVC ratio, mean (SD) | 83.5 (10.9) | 79.7 (10.3) | 87.6 (10.0) | 1.36E − 10 |
Allergen sensitization, no. (%) | 261 (76.5%) | 146 (73%) | 115 (82%) | 0.067 |
Hospitalizations for asthma in the past year, no. (%) | ||||
 0 | 174 (51%) | 174 (87%) | NA |  |
 1 | 11 (3.2%) | 11 (5.5%) | NA |  |
  ≥ 2 | 15 (4.4%) | 15 (7.5%) | NA |  |
Emergency dept visits for asthma in the past year, no. (%) | ||||
 0 | 132 (38.7%) | 132 (66%) | NA |  |
 1 | 20 (5.9%) | 20 (10%) | NA |  |
  ≥ 2 | 48 (14.1%) | 48 (24%) | NA |  |
Rhinosinusitis symptoms, no. (%) | 111 (32.6%) | 82 (41.0%) | 29 (20.6%) | 9.89e − 5 |